Post-earnings recap
Reported
Tue, Aug 11, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
10X Genomics reported a narrower-than-expected loss per share, which was seen as a positive sign by investors. However, the stock reaction remained flat, indicating that investors may be cautious due to the lack of revenue data and guidance. The company's focus on R&D and product demand could position it well for future growth, but uncertainty remains.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | +29.91% |
| Revenue | N/A | N/A | N/A |
Management expressed confidence in the company's long-term strategy. They emphasized the importance of innovation and customer engagement.
Management highlighted ongoing investments in R&D to drive future growth.
They noted a strong demand for their products despite current market challenges.